About Ophthalmic Reconstructive Surgery
Reconstructive surgery of the eye takes place following irreparable damage to the eye’s integrity. Such damage can result following trauma, iatrogenic damage (damage caused during a surgical procedure) or as a result of an inflammatory/connective tissue disease process. In these instances, the tissue can incur such damage that direct and immediate closure becomes impossible, making patching the area with preserved and processed tissue the only treatment option.
CorNeat EverPatch Design Features
Inert and non-degradable material –
Bio-mechanical integration coupled with a minor and progressively subsiding, inflammatory response
Extremely easy to handle and suture
Elastic and durable (cannot be torn by the sutures)
Synthetic and therefore cannot carry or transmit disease
Thin (100 microns), minimizing risk of dellen
Reduces operating time and eye bank costs
Eliminates complexities related to the transportation and storage of biological materials
Readily available, off-the-shelf, device
Substantially longer shelf life than organic/degradable solutions
Translucent when wet
Hardly visible when implanted
The CorNeat EverPatch (scleral patch) is the first synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. It is poised to displace the use of donor and processed tissue, which eventually degrades and carries the risk of disease transmission.
The CorNeat EverPatch is composed of a non-woven, polymer matrix, which integrates with surrounding tissue and is intended to reinforce the sclera and aid the physical reconstruction of the ocular surface.
“The ideal graft material should be long-lasting, sterile, immunologically inactive, cosmetically acceptable, and readily available,” states Seminars in Ophthalmology*. The CorNeat EverPatch was designed with these goals in mind.
*Bains U, Hoguet A. Aqueous Drainage Device Erosion: A Review of Rates, Risks, Prevention, and Repair. Semin Ophthalmol. 2018;33(1):1-10. doi: 10.1080/08820538.2017.1353805. Epub 2017 Dec 6. PMID: 29211548.
Reinforcing the sclera
Aiding the physical reconstruction of the ocular surface
As of June 2023, the CorNeat EverPatch was granted FDA 510(k) clearance.
The current trial is geared toward obtaining a CE Marking early in 2024.
The plans above are subject to regulatory approvals and requirements.